BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10785261)

  • 1. Thiazolidinedione suppresses the expression of erythroid phenotype in erythroleukemia cell line K562.
    Hirase N; Yanase T; Mu Y; Muta K; Umemura T; Takayanagi R; Nawata H
    Leuk Res; 2000 May; 24(5):393-400. PubMed ID: 10785261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of aromatase by nuclear receptors.
    Yanase T; Mu YM; Nishi Y; Goto K; Nomura M; Okabe T; Takayanagi R; Nawata H
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):187-92. PubMed ID: 11850224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiazolidinedione induces apoptosis and monocytic differentiation in the promyelocytic leukemia cell line HL60.
    Hirase N; Yanase T; Mu Y; Muta K; Umemura T; Takayanagi R; Nawata H
    Oncology; 1999 Oct; 57 Suppl 2():17-26. PubMed ID: 10545799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thiazolidinediones inhibit growth of gastrointestinal, biliary, and pancreatic adenocarcinoma cells through activation of the peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha pathway.
    Tsujie M; Nakamori S; Okami J; Hayashi N; Hiraoka N; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
    Exp Cell Res; 2003 Sep; 289(1):143-51. PubMed ID: 12941612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death.
    Guan YF; Zhang YH; Breyer RM; Davis L; Breyer MD
    Neoplasia; 1999 Oct; 1(4):330-9. PubMed ID: 10935488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxisome proliferator-activated receptor (PPAR) gamma and retinoid X receptor (RXR) agonists have complementary effects on glucose and lipid metabolism in human skeletal muscle.
    Cha BS; Ciaraldi TP; Carter L; Nikoulina SE; Mudaliar S; Mukherjee R; Paterniti JR; Henry RR
    Diabetologia; 2001 Apr; 44(4):444-52. PubMed ID: 11357475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined treatment with specific ligands for PPARgamma:RXR nuclear receptor system markedly inhibits the expression of cytochrome P450arom in human granulosa cancer cells.
    Mu YM; Yanase T; Nishi Y; Takayanagi R; Goto K; Nawata H
    Mol Cell Endocrinol; 2001 Jul; 181(1-2):239-48. PubMed ID: 11476957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiazolidinedione effects on glucocorticoid receptor-mediated gene transcription and differentiation in osteoblastic cells.
    Johnson TE; Vogel R; Rutledge SJ; Rodan G; Schmidt A
    Endocrinology; 1999 Jul; 140(7):3245-54. PubMed ID: 10385421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promyelocytic leukemia-specific PML-retinoic acid alpha receptor fusion protein interferes with erythroid differentiation of human erythroleukemia K562 cells.
    Grignani F; Testa U; Fagioli M; Barberi T; Masciulli R; Mariani G; Peschle C; Pelicci PG
    Cancer Res; 1995 Jan; 55(2):440-3. PubMed ID: 7529139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma.
    Haydon RC; Zhou L; Feng T; Breyer B; Cheng H; Jiang W; Ishikawa A; Peabody T; Montag A; Simon MA; He TC
    Clin Cancer Res; 2002 May; 8(5):1288-94. PubMed ID: 12006550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin sensitizer, troglitazone, directly inhibits aromatase activity in human ovarian granulosa cells.
    Mu YM; Yanase T; Nishi Y; Waseda N; Oda T; Tanaka A; Takayanagi R; Nawata H
    Biochem Biophys Res Commun; 2000 May; 271(3):710-3. PubMed ID: 10814527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor.
    Tontonoz P; Singer S; Forman BM; Sarraf P; Fletcher JA; Fletcher CD; Brun RP; Mueller E; Altiok S; Oppenheim H; Evans RM; Spiegelman BM
    Proc Natl Acad Sci U S A; 1997 Jan; 94(1):237-41. PubMed ID: 8990192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo.
    Kubota T; Koshizuka K; Williamson EA; Asou H; Said JW; Holden S; Miyoshi I; Koeffler HP
    Cancer Res; 1998 Aug; 58(15):3344-52. PubMed ID: 9699665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induced myeloid differentiation of K562 cells with downregulation of erythroid and megakaryocytic transcription factors: a novel experimental model for hemopoietic lineage restriction.
    Green AR; Rockman S; DeLuca E; Begley CG
    Exp Hematol; 1993 Apr; 21(4):525-31. PubMed ID: 8462662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A selective peroxisome proliferator-activated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes.
    Mukherjee R; Hoener PA; Jow L; Bilakovics J; Klausing K; Mais DE; Faulkner A; Croston GE; Paterniti JR
    Mol Endocrinol; 2000 Sep; 14(9):1425-33. PubMed ID: 10976920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma.
    Wang Y; Porter WW; Suh N; Honda T; Gribble GW; Leesnitzer LM; Plunket KD; Mangelsdorf DJ; Blanchard SG; Willson TM; Sporn MB
    Mol Endocrinol; 2000 Oct; 14(10):1550-6. PubMed ID: 11043571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel method for analysis of nuclear receptor function at natural promoters: peroxisome proliferator-activated receptor gamma agonist actions on aP2 gene expression detected using branched DNA messenger RNA quantitation.
    Burris TP; Pelton PD; Zhou L; Osborne MC; Cryan E; Demarest KT
    Mol Endocrinol; 1999 Mar; 13(3):410-7. PubMed ID: 10076998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids.
    Asou H; Verbeek W; Williamson E; Elstner E; Kubota T; Kamada N; Koeffler HP
    Int J Oncol; 1999 Nov; 15(5):1027-31. PubMed ID: 10536188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regional differences in the response of human pre-adipocytes to PPARgamma and RXRalpha agonists.
    Sewter CP; Blows F; Vidal-Puig A; O'Rahilly S
    Diabetes; 2002 Mar; 51(3):718-23. PubMed ID: 11872672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions.
    Mehta RG; Williamson E; Patel MK; Koeffler HP
    J Natl Cancer Inst; 2000 Mar; 92(5):418-23. PubMed ID: 10699072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.